You just read:

Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia

News provided by

Convergence Pharmaceuticals

Apr 23, 2013, 07:32 ET